6 of the 20 largest global pharmaceutical companies standardizing on Veeva Vault QMS

PLEASANTON, Calif., May 12, 2021 / PRNewswire / – Large corporations continue to prioritize modernizing quality management. With this change well underway, six of the world’s 20 largest pharmaceutical companies have partnered with Veeva Systems (NYSE: VEEV) to standardize Veeva Vault QMS for greater efficiency and visibility across the enterprise. A growing number of organizations, including more than 175 biopharmaceuticals, contractors, generics and medical technology companies, have adopted Vault QMS to streamline and automate quality processes.

“As a long-time partner, Veeva works closely with us on our digital quality initiatives,” said Nicolás Maldonado, senior director, quality policies and systems at Gilead Sciences. “We are excited to integrate Veeva Vault QMS to simplify, harmonize and automate quality processes across several strategic businesses within Gilead.”

More companies are adopting modern cloud solutions from Veeva to bring together quality processes for greater transparency and real-time visibility across global sites, manufacturing partners and suppliers. Industry leaders partner with Veeva to simplify quality management and increase operational efficiency with a unified quality platform.

“Businesses want a trusted partner who stays focused on customer success for digital quality transformation,” said Mike Jovanis, Vice President, Veeva Vault Quality. “Veeva is committed and will continue to deliver customer-centric innovations throughout product development and manufacture.”

Veeva’s continuous innovation helps customers proactively manage quality and increase their agility. Over the past year, new features in Vault QMS include:

  • Seamless connection between Vault QMS and Veeva Vault registrations to reduce cycle time and increase transparency in post-market change control
  • Advances in Quality Risk Management (QRM) including FMEA methodology to support proactive identification and mitigation of risks
  • Fully automated process allowing external auditors such as marketing managers and suppliers to respond to audit findings directly into the system

Vault QMS is part of Veeva Vault Quality Suite, which includes Veeva Vault QualityDocs, Veeva Vault Training, Veeva Vault Station Manager, and Veeva Vault Product Surveillance to automate and harmonize quality processes globally.

In addition, Veeva announced today that Bluepharma has chosen Vault Quality Suite to unify overall quality management. Read the press release for more information.

Learn more about Vault Quality Suite at the next Veeva R&D and Quality Summit Connect Europe, May 20, 2021. The online event is open to professionals in the life sciences industry. Sign up and stay up to date with program details at veeva.com/Summit.

Further information

To learn more about Veeva Vault QMS, visit: veeva.com/QMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 975 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechnologies. As a public interest company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Forward-looking statements

This release contains forward-looking statements, including market demand and acceptance of Veeva’s products and services, results of use of Veeva’s products and services, and general business conditions (including the continued impact of COVID -19), particularly in the life sciences industry. The forward-looking statements contained in this press release are based on Veeva’s historical performance and its current plans, estimates and expectations, and do not constitute a representation that such plans, estimates or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change and Veeva disclaims any obligation to update any forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties which could cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s filing on Form 10 -K for the period ending January 31. , 2021. This is available on the company’s website at veeva.com in the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other documents filed by Veeva with the SEC from time to time.

SOURCE Veeva Systems

Source link

About Catherine Sherrill

Check Also

Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28%

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us …

Leave a Reply

Your email address will not be published. Required fields are marked *